logo
Product categories

EbookNice.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link.  https://ebooknice.com/page/post?id=faq


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookNice Team

Efficacy, safety, and target engagement of dazukibart, an IFNÃŽÂ2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial by Prof David Fiorentino MD PhD & Aaron R Mangold MD & Prof Victoria P Werth MD & Prof Lisa Christopher-Stine MD & Alisa Femia MD & Myron Chu DO & Prof Amy C M Musiek MD & Jason C Sluzevich MD & Lauren V Graham MD & Anthony P Fernandez MD & Prof Rohit... instant download

  • SKU: EBN-239571736
Zoomable Image
$ 32 $ 40 (-20%)

Status:

Available

0.0

0 reviews
Instant download (eBook) Efficacy, safety, and target engagement of dazukibart, an IFNÃŽÂ2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial after payment.
Authors:Prof David Fiorentino MD PhD & Aaron R Mangold MD & Prof Victoria P Werth MD & Prof Lisa Christopher-Stine MD & Alisa Femia MD & Myron Chu DO & Prof Amy C M Musiek MD & Jason C Sluzevich MD & Lauren V Graham MD & Anthony P Fernandez MD & Prof Rohit...
Pages:updating ...
Year:2025
Publisher:x
Language:english
File Size:1.54 MB
Format:pdf
Categories: Ebooks

Product desciption

Efficacy, safety, and target engagement of dazukibart, an IFNÃŽÂ2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial by Prof David Fiorentino MD PhD & Aaron R Mangold MD & Prof Victoria P Werth MD & Prof Lisa Christopher-Stine MD & Alisa Femia MD & Myron Chu DO & Prof Amy C M Musiek MD & Jason C Sluzevich MD & Lauren V Graham MD & Anthony P Fernandez MD & Prof Rohit... instant download

The Lancet, 405 (2025) 137-146. doi:10.1016/S0140-6736(24)02071-3
*Free conversion of into popular formats such as PDF, DOCX, DOC, AZW, EPUB, and MOBI after payment.

Related Products